Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515728 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL7914906 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL788641 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL25206528 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL198354 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL23234144 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL18970877 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL23016820 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL61278 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL31314689 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107418541-A | It is a kind of to be used to remove descaling and blockage relieving liquid for boring Completion Operations blocking and preparation method thereof | 中国石油集团渤海钻探工程有限公司 | 2017-12-01 | — | — | CN | claimed |
| US-20240376292-A1 | COMPOSITIONS AND METHODS FOR REMOVING BORON FROM AQUEOUS SOLUTIONS | CARBONET NANOTECHNOLOGIES INC. (CA) | 2024-11-14 | — | — | US | disclosed |
| CN-110691609-B | Methods and compositions for inducing an immune response against clostridium difficile | 诺瓦瓦克斯股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11116220-B2 | Antimicrobial compositions with enhanced efficacy | ECOLAB USA INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210235700-A1 | ANTIMICROBIAL COMPOSITIONS WITH ENHANCED EFFICACY | ECOLAB USA INC. | 2021-08-05 | — | — | US | disclosed |
| US-20200359622-A1 | ANTIMICROBIAL ENHANCEMENT OF CATIONIC ACTIVE SKIN ANTISEPTICS | ECOLAB USA INC. | 2020-11-19 | — | — | US | disclosed |
| CN-110691609-A | Methods and compositions for inducing an immune response against clostridium difficile | 诺瓦瓦克斯股份有限公司 | 2020-01-14 | — | — | CN | disclosed |
| US-20190191704-A1 | ANTIMICROBIAL COMPOSITIONS WITH ENHANCED EFFICACY | ECOLAB USA INC. | 2019-06-27 | — | — | US | disclosed |
| CN-108005615-A | A kind of de-plugging construction technology for being used to release the pollution of barium strontium calcium compound scale | 中国石油集团渤海钻探工程有限公司 | 2018-05-08 | — | — | CN | disclosed |
| CN-107418541-A | It is a kind of to be used to remove descaling and blockage relieving liquid for boring Completion Operations blocking and preparation method thereof | 中国石油集团渤海钻探工程有限公司 | 2017-12-01 | — | — | CN | disclosed |
| US-20160338929-A1 | LIQUID NON-IONIC SALT-FREE SKIN AND HAIR TREATMENT COMPOSITION THAT CONTAINS LAUROYL N-METHYL GLUCAMIDE | FORMULA XO, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160338929-A1 | LIQUID NON-IONIC SALT-FREE SKIN AND HAIR TREATMENT COMPOSITION THAT CONTAINS LAUROYL N-METHYL GLUCAMIDE | FORMULA XO, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9393447-B2 | Liquid non-ionic salt-free skin and hair treatment composition that contains Lauroyl N-Methyl Glucamide | FORMULA XO, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9393447-B2 | Liquid non-ionic salt-free skin and hair treatment composition that contains Lauroyl N-Methyl Glucamide | FORMULA XO, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20140242018-A1 | LIQUID NON-IONIC SALT-FREE SKIN AND HAIR TREATMENT COMPOSITION THAT CONTAINS N-METHYL LAUROYL GLUCAMIDE | FORMULA XO, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242018-A1 | LIQUID NON-IONIC SALT-FREE SKIN AND HAIR TREATMENT COMPOSITION THAT CONTAINS N-METHYL LAUROYL GLUCAMIDE | FORMULA XO, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| CN-100383154-C | Gemini boric acid ester glucose acylamine compound, and its preparing method and use | BEIJING GARMENT COLLEGE (CN) | 2008-04-23 | — | — | CN | disclosed |
| CN-1775792-A | Gemini boric acid ester glucose acylamine compound, and its preparing method and use | BEIJING GARMENT COLLEGE (CN) | 2006-05-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160338929-A1 | LIQUID NON-IONIC SALT-FREE SKIN AND HAIR TREATMENT COMPOSITION THAT CONTAINS LAUROYL N-METHYL GLUCAMIDE | UGCG, UGT8, CUTA | EPHX2 4595/4885MEN1 3807/4885KMT2A 247/4885 |
| US-20190191704-A1 | ANTIMICROBIAL COMPOSITIONS WITH ENHANCED EFFICACY | MGAM, GALE, GMDS | EPHX2 2961/4885MEN1 3881/4885KMT2A 2672/4885 |
| US-20140242018-A1 | LIQUID NON-IONIC SALT-FREE SKIN AND HAIR TREATMENT COMPOSITION THAT CONTAINS N-METHYL LAUROYL GLUCAMIDE | UGCG, CUTA, UGT8 | EPHX2 4573/4885MEN1 2893/4885KMT2A 322/4885 |
| US-20210235700-A1 | ANTIMICROBIAL COMPOSITIONS WITH ENHANCED EFFICACY | MGAM, GALE, GMDS | EPHX2 2961/4885MEN1 3881/4885KMT2A 2672/4885 |
| US-20200359622-A1 | ANTIMICROBIAL ENHANCEMENT OF CATIONIC ACTIVE SKIN ANTISEPTICS | CUTA, ARG1, LPO | EPHX2 4362/4885MEN1 4374/4885KMT2A 1413/4885 |
| US-11116220-B2 | Antimicrobial compositions with enhanced efficacy | MGAM, GALE, GMDS | EPHX2 2961/4885MEN1 3881/4885KMT2A 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.